Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuromyelitis Optica.

Dean M Wingerchuk1, Brian G Weinshenker

  • 1Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. wingerchuk.dean@mayo.edu.

Current Treatment Options in Neurology
|April 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunity Gone Viral: Subacute Cognitive Decline With Multifocal Brain Lesions in Neuromyelitis Optica Spectrum Disorder.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Identification of genetic risk loci associated with aquaporin 4-positive neuromyelitis optica spectrum disorder: a genome-wide association study.

The Lancet. Neurology·2026
Same author

Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSD.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study.

Journal of neurology·2025
Same author

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same author

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Neuromyelitis optica (Devic's syndrome) is a rare central nervous system demyelinating disorder. Early diagnosis and specific treatments, including immunosuppression, are crucial for managing this severe, relapsing condition.

Area of Science:

  • Neurology
  • Immunology
  • Neuroimmunology

Background:

  • Neuromyelitis optica (NMO), or Devic's syndrome, is an uncommon CNS demyelinating disorder.
  • It primarily affects the optic nerves and spinal cord, often misdiagnosed as multiple sclerosis.
  • Distinguishing NMO from MS relies on MRI findings, CSF analysis, and specific autoantibody markers.

Purpose of the Study:

  • To differentiate Neuromyelitis optica from Multiple Sclerosis.
  • To outline diagnostic criteria and treatment strategies for NMO.
  • To highlight the role of NMO-IgG autoantibody in diagnosis.

Main Methods:

  • Analysis of clinical presentation, MRI findings (brain and spinal cord), and cerebrospinal fluid (CSF) analysis.
  • Identification and utilization of the NMO-IgG serum autoantibody marker.

Related Experiment Videos

  • Review of treatment outcomes for acute exacerbations and relapse prevention.

    • Main Results:

    • NMO is characterized by longitudinally extensive spinal cord lesions and normal brain MRI.
    • CSF analysis reveals polymorphonuclear pleocytosis and absence of oligoclonal banding.
    • NMO-IgG autoantibody is highly specific for diagnosing Devic's syndrome.

    Conclusions:

    • NMO is a distinct demyelinating syndrome from MS, requiring specific diagnostic approaches.
    • Acute attacks are treated with corticosteroids and plasmapheresis for refractory cases.
    • Long-term management involves systemic immunosuppression (azathioprine, corticosteroids) or humoral immunotherapy (rituximab) for severe cases.